Public Company

Brainstorm Cell Therapeutics

About

Brainstorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the FDA and the EMA for the treatment of amyotrophic lateral sclerosis (ALS).

Overview

Founded 2004
Type Public
Location New York, New York, USA

Stock

BCLI $1.50 -8.04% $(0.13)

Latest News

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday Nov 23, 2022 Benzinga Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its...
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More Nov 16, 2022 Zacks Investment Research Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday Nov 11, 2022 Benzinga Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast Radius received Bankruptcy court...
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session Nov 10, 2022 Benzinga Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day...
22 Stocks Moving in Monday's Pre-Market Session Jun 07, 2021 Benzinga Gainers Liminal BioSciences Inc. (NASDAQ: LMNL) rose 51.7% to $6.10 in pre-market trading. Liminal BioSciences reported the FDA approval for its Biologics License Application for...